DelveInsight’s "Inflammatory bowel disease (IBD)—Epidemiology Forecast-2032" report delivers an in-depth understanding of the IBD, historical and forecasted epidemiology as well as the IBD trends in the APAC region (Australia, China, India, Japan, and South Korea).
Inflammatory bowel disease (IBD) Disease Understanding
The digestive system is one of the largest organ systems in the human body. It starts from the external opening, ‘mouth,’ from where the food is ingested and finishes at the other external opening ‘anus,’ from where the remaining material after the digestion of the food is expelled out of the body. Like any other part of the body, the digestive system and its organs are affected by different ailments, inflammatory bowel disease (IBD) being one of them. Inflammatory bowel disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of any part of the digestive tract. The digestive tract comprises the:
• mouth
• esophagus
• stomach
• small intestine
• large intestine
It is responsible for:
• breaking down food
• extracting nutrients
• removing any unusable material and waste products (Healthline, n.d.)
The inflammation in the digestive tract affects its normal functioning and hampers the nutrient uptake by the body. It is a chronic condition, which means it lasts a long time or constantly comes and goes. There are two kinds of IBD: Crohn’s disease (CD) and Ulcerative colitis (UC). These diseases have many things in common, but there are important differences.
Continued in the report…..
Inflammatory bowel disease (IBD) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Number of Prevalent Cases of Inflammatory Bowel Disease (IBD), Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), and Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) scenario in the APAC region (Australia, China, India, Japan, and South Korea) from 2018 to 2030.
Inflammatory bowel disease (IBD) Detailed Epidemiology Segmentation
• Total prevalent population of IBD in the APAC regions was 3,907,112 cases in 2021 which is expected to increase during the study period.
• Japan accounted for third highest (205,859) cases of IBD, compared to other Asian regions (China (1,917,172 cases), India (1,566,102 cases), Australia (168,539 cases), and South Korea (49,440 cases)) in 2021.
• Males accounted for higher number of IBD cases in the APAC region in 2021. There were 1,708,495 cases and 1,293,034 cases of IBD in males and females respectively in 2021.
• The maximum number of prevalent IBD cases in the APAC region were found in the age group 40+ years, followed by those aged 20–39 years. As per estimates, the age group of 40+ years contributed to 1,549,013 cases in 2021, which is anticipated to increase throughout the study period 2018─2030.
• IBD patients are further classified based on the severity of the disease. Patients with mild, and moderate to severe accounts for approximately 1,014,670 cases, and 1,986,860 cases respectively in 2021.
Scope of the Report
• The report covers the descriptive overview of IBD, explaining its causes, symptoms, pathophysiology, and other aspects.
• The report provides insight into the APAC region’s historical and forecasted patient pool covering Australia, China, India, Japan, and South Korea.
• The report assesses the disease risk and burden and highlights the unmet needs of Inflammatory bowel disease (IBD).
• The report helps to recognize the growth opportunities in the APAC region with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for APAC region (Australia, China, India, Japan, and South Korea) by Number of Prevalent Cases of Inflammatory Bowel Disease (IBD), Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), and Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD).
Report Highlights
• 9-Year Forecast of IBD
• APAC region (Australia, China, India, Japan, and South Korea) Coverage
• Number of Prevalent Cases of Inflammatory Bowel Disease (IBD)
• Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD)
• Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD)
• Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD)
• Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD), and
• Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD)
Key Questions Answered
• What are the disease risk, and burden of IBD?
• What is the historical IBD patient pool in the APAC region (Australia, China, India, Japan, and South Korea)?
• What would be the forecasted patient pool of IBD at the APAC region level?
• What will be the growth opportunities across the APAC region with respect to the patient population pertaining to IBD?
• Out of the above-mentioned countries, which country would have the highest prevalent population of IBD during the forecast period (2022–2030)?
• At what CAGR the population is expected to grow across the APAC region during the forecast period (2022–2030)?
Reasons to buy
The Inflammatory bowel disease (IBD) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the APAC IBD epidemiology forecast.
• The IBD epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The IBD epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 9-year forecast period using reputable sources.
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• Australia
• China
• India
• Japan
• South Korea
Study Period: 2018–2030
- 1 Key Insights
- 2 Report Introduction
- 3 Inflammatory Bowel Disease (IBD) Epidemiology Overview at a Glance
- 3.1 Epidemiology Share (%) of Inflammatory Bowel Disease (IBD) by Therapies in 2018
- 3.2 Epidemiology Share (%) of Inflammatory Bowel Disease (IBD) by Therapies in 2030
- 4 Executive Summary of Inflammatory Bowel Disease (IBD)
- 5 Key Events
- 6 Inflammatory bowel disease (IBD): Disease Background and Overview
- 6.1 Introduction
- 6.2 Signs and symptoms
- 6.3 Types of IBD: Crohn’s Disease and Ulcerative Colitis
- 6.4 Causes of Inflammatory bowel disease (IBD)
- 6.5 Pathophysiology and Genetics of Inflammatory bowel disease (IBD)
- 6.5.1 Genetics
- 6.5.2 Microbial Factors
- 6.5.3 Immunological Factors
- 6.5.3.1 Innate immunity
- 6.5.3.2 Adaptive immunity
- 6.5.4 Environmental Factors
- 6.6 Diagnosis of Inflammatory bowel disease (IBD)
- 6.6.1 Laboratory Tests
- 6.6.2 Imaging Tests
- 6.7 Treatment of Inflammatory bowel disease (IBD)
- 6.7.1 Medications
- 6.7.2 Surgery
- 6.7.3 Lifestyle Changes
- 6.8 Inflammatory bowel disease (IBD) Diagnosis and Management Guidelines
- 6.8.1 Asian Organization for Crohn’s and Colitis (AOCC) and Asia Pacific Association of Gastroenterology Recommendations
- 6.8.1.1 Pretreatment evaluation
- 6.8.1.2 Medical management of active inflammatory bowel disease
- 6.8.1.3 Medical management of inflammatory bowel disease in remission
- 6.8.1.4 Management of inflammatory bowel disease during the periconception period and pregnancy
- 6.8.1.5 Surveillance strategies for colitis-associated cancer
- 6.8.1.6 Monitoring adverse events of thiopurines and methotrexate
- 6.8.1.7 Infections in inflammatory bowel disease
- 7 Epidemiology and Patient Population
- 7.1 Key Findings
- 7.2 Methodology
- 7.3 Assumptions and Rationale: APAC Region
- 7.4 Total Prevalent Cases of Inflammatory Bowel Disease (IBD) in the APAC Region
- 7.5 Total Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the APAC Region
- 7.6 Australia
- 7.6.1 Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia
- 7.6.2 Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia
- 7.6.1 Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia
- 7.6.2 Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia
- 7.6.3 Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia
- 7.6.4 Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia
- 7.7 China
- 7.7.1 Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in China
- 7.7.2 Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China
- 7.7.3 Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China
- 7.7.4 Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China
- 7.7.5 Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China
- 7.7.6 Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China
- 7.8 India
- 7.8.1 Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in India
- 7.8.2 Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India
- 7.8.3 Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India
- 7.8.4 Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India
- 7.8.5 Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India
- 7.8.6 Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India
- 7.9 Japan
- 7.9.1 Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan
- 7.9.2 Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan
- 7.9.3 Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan
- 7.9.4 Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan
- 7.9.5 Severity-specific Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan
- 7.9.6 Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan
- 7.10 South Korea
- 7.10.1 Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea
- 7.10.2 Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea
- 7.10.3 Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea
- 7.10.4 Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea
- 7.10.5 Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea
- 7.10.6 Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea
- 8 Patient Journey
- 9 Appendix
- 9.1 Report Methodology
- 9.2 Bibliography
- 10 DelveInsight Capabilities
- 11 Disclaimer
- 12 About DelveInsight
- Table 1: Key Events
- Table 2: Total Prevalent Cases of Inflammatory Bowel Disease (IBD) in APAC Region in ‘000’(2018–2030)
- Table 3: Total Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the APAC Region in ‘000’ (2018–2030)
- Table 4: Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia, in ‘000’ (2018–2030)
- Table 5: Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia, in ‘000’ (2018–2030)
- Table 6: Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia, in ‘000’ (2018–2030)
- Table 7: Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia, in ‘000’ (2018–2030)
- Table 8: Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia, in ‘000’ (2018–2030)
- Table 9: Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia, in ‘000’ (2018–2030)
- Table 10: Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in China, in ‘000’ (2018–2030)
- Table 11: Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China, in ‘000’ (2018–2030)
- Table 12: Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China, in ‘000’ (2018–2030)
- Table 13: Type–Specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China, in ‘000’ (2018–2030)
- Table 14: Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China, in ‘000’ (2018–2030)
- Table 15: Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China, in ‘000’ (2018–2030)
- Table 16: Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in India, in ‘000’ (2018–2030)
- Table 17: Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India, in ‘000’ (2018–2030)
- Table 18: Gender–Specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India, in ‘000’ (2018–2030)
- Table 19: Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India, in ‘000’ (2018–2030)
- Table 20: Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India, in ‘000’ (2018–2030)
- Table 21: Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India, in ‘000’ (2018–2030)
- Table 22: Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan, in ‘000’ (2018–2030)
- Table 23: Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan, in ‘000’ (2018–2030)
- Table 24: Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan, in ‘000’ (2018–2030)
- Table 25: Type–Specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan, in ‘000’ (2018–2030)
- Table 26: Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan, in ‘000’ (2018–2030)
- Table 27: Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan, in ‘000’ (2018–2030)
- Table 28: Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea, in ‘000’ (2018–2030)
- Table 29: Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea, in ‘000’ (2018–2030)
- Table 30: Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea, in ‘000’ (2018–2030)
- Table 31: Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea, in ‘000’ (2018–2030)
- Table 32: Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea, in ‘000’ (2018–2030)
- Table 33: Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea, in ‘000’ (2018–2030)Figure 1: Signs and symptoms of IBD
- Figure 2: Diagnostic Tests for IBD
- Figure 3: Treatment options for IBD
- Figure 4: Total Prevalent Cases of Inflammatory Bowel Disease (IBD) in APAC Region (2018–2030)
- Figure 5: Total Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in the APAC Region (2018–2030)
- Figure 6: Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia (2018–2030)
- Figure 7: Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia (2018–2030)
- Figure 8: Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia (2018–2030)
- Figure 9: Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia (2018–2030)
- Figure 10: Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia (2018–2030)
- Figure 11: Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Australia (2018–2030)
- Figure 12: Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in China (2018–2030)
- Figure 13: Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China (2018–2030)
- Figure 14: Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China (2018–2030)
- Figure 15: Type–Specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China (2018–2030)
- Figure 16: Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China (2018–2030)
- Figure 17: Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in China (2018–2030)
- Figure 18: Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in India (2018–2030)
- Figure 19: Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India (2018–2030)
- Figure 20: Gender–Specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India (2018–2030)
- Figure 21: Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India (2018–2030)
- Figure 22: Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India (2018–2030)
- Figure 23: Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in India (2018–2030)
- Figure 24: Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan (2018–2030)
- Figure 25: Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan (2018–2030)
- Figure 26: Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan (2018–2030)
- Figure 27: Type–Specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan (2018–2030)
- Figure 28: Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan (2018–2030)
- Figure 29: Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in Japan (2018–2030)
- Figure 30: Number of Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea (2018–2030)
- Figure 31: Number of Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea (2018–2030)
- Figure 32: Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea (2018–2030)
- Figure 33: Type-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea (2018–2030)
- Figure 34: Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea (2018–2030)
- Figure 35: Age-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD) in South Korea (2018–2030)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook